Adverse events associated with potential drugs for COVID-19: a case study from real-world data.
COVID-19
adverse events
real-world data
Journal
Briefings in bioinformatics
ISSN: 1477-4054
Titre abrégé: Brief Bioinform
Pays: England
ID NLM: 100912837
Informations de publication
Date de publication:
22 03 2021
22 03 2021
Historique:
received:
29
06
2020
revised:
03
08
2020
accepted:
26
08
2020
pubmed:
2
10
2020
medline:
15
4
2021
entrez:
1
10
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) has resulted as a global pandemic. The World Health Organization announced the most promising drugs in SOLIDARITY for the global trial, and several other drugs are under investigation through ongoing clinical trials to prove the effectiveness and safety of potential therapeutics. Here, we depicted the safety profile of these drugs and investigated their associated adverse events (AEs). We observed the associated AEs in different organs/systems, especially in skin and subcutaneous tissue, immune system and musculoskeletal and connective tissue. Furthermore, we observed strong bias of AEs in different groups of sex and age. Our study provides knowledge of the toxicity of potential COVID-19 drugs. While these drugs hold promise to fight the global pandemic, healthcare providers should pay attention to AEs to maximize the treatment benefit while minimizing toxicity.
Identifiants
pubmed: 33003194
pii: 5917051
doi: 10.1093/bib/bbaa234
pmc: PMC7543289
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1232-1238Subventions
Organisme : NIAID NIH HHS
ID : R21 AI150085
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK090570
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.